Aardvark Therapeutics, Inc. Common Stock (AARD) Stock

Aardvark Therapeutics, Inc. Common Stock (AARD) is a Healthcare stock trading at $3.92 (as of 2026-06-18), with a market capitalization of $83.12M and a trailing P/E of -1.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies designed to engage innate homeostatic mechanisms to treat metabolic conditions. Its pipeline includes ARD-101 for hyperphagia and ARD-201 for obesity, with studies in Phases I through III.

Valuation — source: SEC EDGAR (first-party)
Price	$3.92
Market Cap	$83.12M
P/E Ratio	-1.2
EV / EBITDA	-0.3
Price / Book	0.98
DCF Value (model)	$-40.19
DCF Upside vs Price	-1123.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-80.3%
Current Ratio	8.06
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	-43.1%
FCF Growth (YoY)	198.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	2.76 (grey)

Valuation vs Sector & Industry
Stock P/E	-1.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-105.8%
vs Industry	-107.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Decheng Capital LLC ($14.77M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Tien-Li Lee
Employees	22
Country	US
IPO Date	2025-03-31

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.